U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07823205) titled 'A Study to Evaluate Different Oral Formulations of KT-621' on Sept. 11.
Brief Summary: This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: KT-621
KT-621 Reference Oral Formulation
DRUG: KT-621
KT-621 Test Oral Formulation #1
DRUG: KT-621
KT-621 Test Oral Formulation #2
Recruitment Status: RECRUITING
Sponsor: Kymera Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health...